# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price ...
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the t...
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...
Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one pa...